FDA Action-Item List Shows Plans To Revamp De Novo, Combo Product, QSR Regs, And More

Planned US FDA actions on the spring 2020 Agency Rule List show expected rules around de novo applications, and combination product classification and appeals – as well as the long-awaited Quality System Regulation overhaul.